Increased loss of trabecular but not cortical bone density, 1 year after discontinuation of 2 years hormone replacement therapy with Tibolone

Maturitas

Volumn 31, Issue 2, 1999, Pages 151-159

  Berning, Bernd ^a   V Kuijk, Cornelis ^a   Kuiper, Jan W ^a   Coelingh Bennink, Herjan J T ^b   Fauser, Bart C J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Research and Development   (Netherlands)

Author keywords

Bone density loss; Hormone replacement therapy; Quantitative computed tomography (QCT); Tibolone

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CREATININE; HYDROXYPROLINE; PHOSPHORUS; TIBOLONE;

ARTICLE; BONE DENSITY; BONE METABOLISM; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICAL BONE; DOSE RESPONSE; FEMALE; FOLLOW UP; MAJOR CLINICAL STUDY; MENOPAUSE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; SUBSTITUTION THERAPY; TRABECULAR BONE;

ANABOLIC AGENTS; BONE DENSITY; BONE RESORPTION; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NORPREGNENES;

EID: 0033012178     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(98)00089-9     Document Type: Article

References (31)

1. Ettinger B., Genant H.K., Cann C.E. Postmenopausal bone loss is prevented with low-dosage estrogen with calcium. Ann Intern Med. 106:1987;40-45.
2. Riis B.J., Thomsen K., Strom V., Christiansen C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol. 156:1987;61-65.
3. Stevenson J.C., Cust M.P., Gangar K.F., Hillard T.C., Lees B., Whitehead M.I. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet. 335:1990;265-269.
4. Marslew U., Overgaard K., Riis B.J., Christiansen C. Two new combinations of estrogen and progestagen for prevention of postmenopausal bone loss: long-term effects on bone, climacteric symptoms, and bleeding. Obstet Gynecol. 79:1992;202-210.
5. Lindsay R., Hart D.M., MacLean A., Clark A.C., Kraszewski A., Garwood J. Bone response to termination of estrogen treatment. Lancet. i:1978;1325-1327.
6. Horsman A., Nordin B.E.C., Crilly R.G. Effect on bone of withdrawal of oestrogen therapy. Lancet. i:1979;33.
7. Fogelman I., Bessant R.G., Cohen H.N., Hart D.M., Lindsay R. Skeletal uptake of diphosphonate. Method for prediction of postmenopausal osteoporosis. Lancet. ii:1980;667-670.
8. Christiansen C., Christensen M.S., Transbol I.B. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet. i:1981;459-461.
9. Thomsen K., Riis B.J., Johansen J.S., Christiansen C., Rodbro P. Bone turnover in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy. Gynecol Endocrinol. 1:1987;169-175.
10. Felson D.T., Zhang M.P.H.Y., Hannan M.T., Kiel D.P., Wilson P.W.F., Anderson J.J. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med. 329:1993;1141-1146.
11. Schneider D.L., Barrett-Connor E.L., Morton D.J. Timing of postmenopausal estrogen for optimal bone mineral density. J Am Med Assoc. 277:1997;543-547.
12. de Visser J., Coert A., Feenstra H., van der Vies J. Endocrinology studies with Org OD 14. Arzeneimittelforsch/Drug Res. 34:1984;1010-1017.
13. Lindsay R., Hart D.M., Kraszewski A. Prospective double blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J. 280:1980;1207-1209.
14. Rymer J., Chapman M.G., Fogelman I. Effect of Tibolone on postmenopausal bone mass. Osteoporosis Int. 4:1994;314-319.
15. Berning B., van Kuijk C., Kuiper J.W., Coelingh Bennink H.J.T., Kicovic P.M., Fauser B.C.J.M. Effects of two doses of Tibolone on trabecular and cortical bone loss in early postmenopausal women: A 2-year randomized, placebo-controlled study. Bone. 19:1996;395-399.
16. Bjarnason H.N., Bjarnason K., Haarbo J., Rosenquist C., Christiansen C. Tibolone: Prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab. 81:1996;2419-2422.
17. Fogelman I., Bessant R.G., Smith M.L., Hart D.M., Lindsay R. Assessment of synthetic steroid (Org OD 14): effect on skeletal metabolism by 24-H whole retention of diphosphonate. Maturitas. 3:1981;265-269.
18. Lindsay P.C., Shaw R.C., Coelingh Bennink H.J.T., Kicovic P.M. The effect of add-back treatment with Tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl). Fertil Steril. 65:1996;342-348.
19. Lyritis G.P., Karpathios S., Basdekis K. et al. Prevention of post-oophorectomy bone loss with Tibolone. Maturitas. 22:1995;247-253.
20. Sandor T., Kalender W.A., Hanlon W.B., Weissman B.N., Rumbaugh C. Spinal bone determination using automated contour detection: application for single and dual energy CT. SPIE. 555:1985;188-194.
21. Trouerbach W.Th., Birkenhäger J.C., Schmitz P.I.M.et al. A cross-sectional study of age related loss of mineral content of phalangeal bone in men and women. Skeletal Radiol. 17:1988;338-343.
22. Berning B., van Kuijk C., Schütte H.E., Kuiper J.W., Drogendijk A.C., Fauser B.C.J.M. Determinants of lumbar bone mineral density in normal weight, non-smoking women soon after menopause. A study using clinical data and quantitative computed tomography. Bone Miner. 21:1993;129-139.
23. Dempster DW. Bone remodelling. In: Cloe F, Favus MJ, editors. Disorders of Bone and Mineral Metabolism. New York: Raven Press, 355-382.
24. Parfitt AM. The physiological an clinical significance of bone histomorphometric data. In: Recker R, editor. Bone Histomorphometry: Techniques and Interpretations. Boca Raton, FL: CRC Press, 1979:143-223.
25. Genant H.K., Cann C.E., Ettinger B., Gordon G.S. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early postmenopausal after oophorectomy. Ann Intern Med. 97:1982;699-705.
26. Nilas L., Borg J., Gotfredsen A., Christiansen C. Comparison of single- and dual photon absorptiometry in postmenopausal bone mineral loss. J Nucl Med. 26:1985;1257-1262.
27. Wornski T.J., Dann L.M., Qi H., Yen C.F. Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomized Rats. Calcif Tissue Int. 53:1993;210-216.
28. Takahashi K., Tsuboyama T., Matsushita M.et al. Effective intervention of peak bone mass and bone modelling in the spontaneous murine model of senile osteoporosis, sam-p/6, by Ca supplement and hormone treatment. Bone. 15:1994;209-215.
29. Davis J.W., Ross P.D., Johnson N.E., Wasnich R.D. Estrogen and calcium supplement use among Japanese-American women: Effects upon bone loss when used singly and in combination. Bone. 17:1995;369-373.
30. Ettinger B., Grady D. The waning effect of postmenopausal estrogen therapy on osteoporosis. N Engl J Med. 329:1993;1192-1193.
31. Riggs B.L. Editorial: Tibolone as an alternative to estrogen for the prevention of postmenopausal osteoporosis in selected postmenopausal women. J Clin Endocrinol Metab. 81:1996;2417-2418.